{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.259","paramType":"Hazard Ratio (HR)","paramValue":"0.90","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.27","upperLimit":"54.24","value":"43.1"},{"groupId":"OG001","lowerLimit":"23.46","upperLimit":"53.75","value":"41.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"OG000","title":"Everolimus + BSC"},{"description":"Participants received matching placebo once daily plus BSC during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"The full analysis set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients were analyzed according to the treatment arm and stratification factors they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death, assessed up to approximately 8 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}